Security key
87975F104
Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO)
CUSIP: 87975F104
Q4 2025 13F Holders as of 31 Dec 2025
- Security type / class
- Equity / Common Stock, no par value
- Total 13F shares
- 2,285,727
- Total 13F value
- $3,040,166
- Share change
- -46,337
- SEC-reported price per share
- $1.33
- Number of holders
- 33
- Value change
- -$68,478
- Number of buys
- 12
- Number of sells
- 13
- Shares outstanding
- 68,772,896
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2025
Institutions
33
Top holders
10
TELO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q1 2026
Previous quarter: Q3 2025
Telomir Pharmaceuticals, Inc. SEC filings
Telomir Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 87975F104
Recent filing periods:
Ownership snapshot
Top reported holders of TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Bay Shore Trust
Disclosed value leader
Bay Shore Trust
Comparable rows
0/15
Latest evidence
30 Sep 2025
3/4/5
13F
Highest disclosed value: $20,414,715
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
Bay Shore Trust has the largest disclosed position value at $20.41M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Bay Shore Trust's linked filing trail.
Disclosed position value
Top 5
Bay Shore Trust
$20.41M
MIRA PHARMACEUTICALS, INC.
$4.82M
Christopher Chapman MD
$6.05M
Craig Eagle
$3.02M
VANGUARD GROUP INC
$1.53M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Bay Shore Trust |
3/4/5
10%+ Owner
|
—
mixed-class rows
|
$20,414,715
5,631,721 shares
mixed-class rows
|
— | 21 Nov 2024 |
| MIRA PHARMACEUTICALS, INC. |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$4,823,943
3,521,127 shares
|
— | 29 Sep 2025 |
| Christopher Chapman MD |
3/4/5
CEO & Chairman, Director
|
—
denominator unverified
|
$6,048,782
975,610 shares
|
— | 08 Feb 2024 |
| Craig Eagle |
3/4/5
Director
|
—
denominator unverified
|
$3,024,391
487,805 shares
|
— | 08 Feb 2024 |
| VANGUARD GROUP INC |
13F
Company
|
—
denominator unverified
|
$1,531,435
1,101,752 shares
|
— | 30 Sep 2025 |
| Nathen Fuentes |
3/4/5
Chief Financial Officer
|
—
denominator unverified
|
$627,031
101,134 shares
|
— | 08 Feb 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
33
Shares
2,285,727
Rows available
33
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
31
Q4 2025 holders
33
Holder diff
2
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend